In8Bio (INAB) Return on Capital Employed (2021 - 2026)
In8Bio (INAB) posted Return on Capital Employed of 70.0% for Q1 2026, up 23.08% sequentially from 90.99% in Q4 2025, and up 8717.0% YoY from 0.79% in Q1 2025.
In8Bio (INAB) Return on Capital Employed (2021 - 2026) Analysis & Trends
In8Bio has reported Return on Capital Employed for 6 years, with the latest figure at 70.0% in Q1 2026.
- Quarterly Return on Capital Employed rose 8717.0% year-over-year to 70.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 70.0% (up 8717.0% YoY) and the FY2025 annual result came in at 82.89%, up 4265.0% from the prior year.
- Return on Capital Employed grew to 70.0% in Q1 2026 per INAB's latest filing, from 90.99% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 49.41% in Q1 2022 and troughed at 204.38% in Q3 2024.
- A 5-year average of 119.35% and a median of 122.15% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 7585 bps in 2024, then soared 10701 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 95.42% in 2022, then dropped by 28 bps to 122.15% in 2023, then slumped by 62 bps to 198.0% in 2024, then surged by 54 bps to 90.99% in 2025, then gained by 23 bps to 70.0% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 70.0%, 90.99%, and 126.22% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 7.88% |
| 10 | In8Bio | 23.75 Mn | 23.75 Mn | - | -85.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.82% |
| Mar 31, 2026 | -70.00% |
| Dec 31, 2025 | -90.99% |
| Sep 30, 2025 | -126.22% |
| Jun 30, 2025 | -135.23% |
| Mar 31, 2025 | -157.17% |
| Dec 31, 2024 | -198.00% |
| Sep 30, 2024 | -204.38% |
| Dec 31, 2023 | -122.15% |
| Sep 30, 2023 | -129.77% |
| Jun 30, 2023 | -129.98% |
| Mar 31, 2023 | -119.08% |
| Dec 31, 2022 | -95.42% |
| Sep 30, 2022 | -89.21% |
| Jun 30, 2022 | -73.28% |
| Mar 31, 2022 | -49.41% |
| Dec 31, 2021 | -34.54% |
| Sep 30, 2021 | -36.82% |